File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: α-Interferon treatment in Chinese patients with chronic hepatitis B

Titleα-Interferon treatment in Chinese patients with chronic hepatitis B
Authors
Issue Date1990
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 1990, v. 11 SUPPL. 1, p. S121-S125 How to Cite?
Abstractα-Interferon has been shown to be the most promising antiviral agent in the treatment of chronic hepatitis B virus infection in Caucasian patients. The experience with recombinant interferon alfa-2a and alfa-2b in four randomized controlled trials in Chinese adults and children is reviewed here. α-Interferon alone has little long-term benefit in the treatment of Chinese patients with chronic hepatitis B virus infection, especially in patients who have normal or near normal serum aminotransferase levels. The response in patients with elevated aminotransferase levels appears to be better. The poor antiviral response in patients with normal aminotransferase levels is probably due to immunological tolerance to HBV induced by exposure to the virus in early life. Prednisone pretreatment does not seem to have any additional benefit to using interferon alone in these patients, while the effect in patients with elevated aminotransferase levels remains to be proven.
Persistent Identifierhttp://hdl.handle.net/10722/163527
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLos, ASFen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorLeung, EKYen_US
dc.contributor.authorWong, LSKen_US
dc.contributor.authorFung, YLen_US
dc.date.accessioned2012-09-05T05:37:05Z-
dc.date.available2012-09-05T05:37:05Z-
dc.date.issued1990en_US
dc.identifier.citationJournal Of Hepatology, 1990, v. 11 SUPPL. 1, p. S121-S125en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/163527-
dc.description.abstractα-Interferon has been shown to be the most promising antiviral agent in the treatment of chronic hepatitis B virus infection in Caucasian patients. The experience with recombinant interferon alfa-2a and alfa-2b in four randomized controlled trials in Chinese adults and children is reviewed here. α-Interferon alone has little long-term benefit in the treatment of Chinese patients with chronic hepatitis B virus infection, especially in patients who have normal or near normal serum aminotransferase levels. The response in patients with elevated aminotransferase levels appears to be better. The poor antiviral response in patients with normal aminotransferase levels is probably due to immunological tolerance to HBV induced by exposure to the virus in early life. Prednisone pretreatment does not seem to have any additional benefit to using interferon alone in these patients, while the effect in patients with elevated aminotransferase levels remains to be proven.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshChina - Ethnologyen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshHepatitis B - Blood - Therapyen_US
dc.subject.meshHepatitis B Core Antigens - Analysisen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshInterferon-Alpha - Therapeutic Useen_US
dc.subject.meshPrednisone - Therapeutic Useen_US
dc.subject.meshRecombinant Proteinsen_US
dc.titleα-Interferon treatment in Chinese patients with chronic hepatitis Ben_US
dc.typeConference_Paperen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0168-8278(90)90177-Sen_US
dc.identifier.pmid2079568-
dc.identifier.scopuseid_2-s2.0-0025602039en_US
dc.identifier.volume11en_US
dc.identifier.issueSUPPL. 1en_US
dc.identifier.spageS121en_US
dc.identifier.epageS125en_US
dc.identifier.isiWOS:A1990ET84700019-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridLos, ASF=6603669016en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridLeung, EKY=25224640000en_US
dc.identifier.scopusauthoridWong, LSK=7402091922en_US
dc.identifier.scopusauthoridFung, YL=36612744400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats